The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
The Neurotoxicant, Cuprizone, as a Model to Study Demyelination and Remyelination in the Central Nervous System
Open accessAbstract
Myelin of the adult CNS is vulnerable to a variety of metabolic, toxic, and autoimmune insults. That remyelination can ensue, following demyelinating insult, has been well demonstrated. Details of the process of remyelination are, however difficult to ascertain since in most experimental models of demyelination/remyelination the severity, localization of lesion site, or time course of the pathophysiology is variable from animal to animal. In contrast, an experimental model in which massive demyelination can be reproducibly induced in large areas of mouse brain is exposure to the copper chelator, cuprizone, in the diet. We review work from several laboratories over the past 3 decades, with emphasis on our own recent studies, which suggest an overall picture of cellular events involved in demyelination/remyelination. When 8 week old C57BL/6 mice are fed 0.2% cuprizone in the diet, mature olidgodendroglia are specifically insulted (cannot fulfill the metabolic demand of support of vast amounts of myelin) and go through apoptosis.This is closely followed by recruitment of microglia and phagoctytosis of myelin. Studies of myelin gene expression, coordinated with morphological studies, indicate that even in the face of continued metabolic challenge, oligodendroglial progenitor cells proliferate and invade demyelinated areas. If the cuprizone challenge is terminated, an almost complete remyelination takes place in a matter of weeks. Communication between different cell types by soluble factors may be inferred. This material is presented in the context of a model compatible with present data—and which can be tested more rigorously with the cuprizone model. The reproducibility of the model indicates that it may allow for testing of manipulations (e.g. available knockouts or transgenics on the common genetic background, or pharmacological treatments) which may accelerate or repress the process of demyelination and or remyelination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The C57BL/6 mice showed a dramatic loss of myelin staining at this time point (Fig. 1b), which is consistent with previous reports [5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Upon treatment with cuprizone, mice typically exhibit profound demyelination in the corpus callosum, the cortex and the superior cerebellar peduncles [4, 5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most investigators use the standard C57BL/6 mouse strain in the cuprizone model to study the different molecular components involved in the complex pathogenic processes leading to corpus callosum demyelination [5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the corpus callosum, apoptosis of oligodendrocytes is observed, together with recruitment of microglia/macrophages, astrocytes and oligodendrocyte progenitor cells (OPCs) [5, 6].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, the continuous exposure of C57BL/6 mice to cuprizone results in a pattern of two cycles of demyelination and remyelination, followed by chronic demyelination from which animals do not recover 36, 39.”
From SJL Mice Exposed to Cuprizone Intoxication Reveal Strain and Gender Pattern Differences in Demyelination (2009) · cites this paper as [39]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, C57BL/6 mice experience a spontaneous partial remyelination after 6 weeks and then continue to demyelinate further when exposed continuously to cuprizone 36, 39.”
From SJL Mice Exposed to Cuprizone Intoxication Reveal Strain and Gender Pattern Differences in Demyelination (2009) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, unlike microglia and astrocytes in C57BL/6 mice that respond vigorously to demyelination 2, 23, 39, these cell types in SJL mice have a guarded response at midline and in the lateral region, which correlates with subdued demyelination.”
From SJL Mice Exposed to Cuprizone Intoxication Reveal Strain and Gender Pattern Differences in Demyelination (2009) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cuprizone toxicity produces profound demyelination in the white and grey matter of the brain that mirrors sites of MS pathology [46].”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other features common to both cuprizone-induced and type 3 MS lesions are mitochondrial stress, selective loss of myelin-associated glycoprotein (MAG), lesions with indistinct borders that are not perivascular, pronounced glial activation, and lymphocyte infiltration [43, 46, 65, 69–71].”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The histopathological hallmark of the cuprizone model as standardized by Hiremath is oligodendrocyte death and subsequent demyelination in the corpus callosum, superior cerebellar peduncles, hippocampus [42, 46–54] and several other areas of the mouse brain (reviewed in [20]).”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglial activation and axonal loss positively correlate with demyelination and the reproducible lesion localization – primarily in the corpus callosum [186], cerebellar peduncle [186], hippocampus [187], and cortex [184, 185, 188] – mirrors the topographical specificity of MS pathology, including subpial cortical demyelination seen in PMS patients.”
From Insights and challenges on animal models for progressive multiple sclerosis (2026) · cites this paper as [186]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remyelination is very robust in the cuprizone model and starts directly after demyelination is complete, irrespective if cuprizone is further fed or not (Matsushima and Morell, 2001; Hiremath et al., 2008; Gudi et al., 2009).”
From Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned (2014) · cites this paper as Matsushima and Morell, 2001
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Depletion of microglia likewise prevented the loss of oligodendrocytes (OLs) in the CC that normally results from CUP treatment (Matsushima & Morell, 2001).”
From Activated microglia drive demyelination via CSF1R signaling (2021) · cites this paper as Matsushima & Morell, 2001
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The cuprizone model involves administration of the toxin cuprizone to induce oligodendrocyte apoptosis [4, 5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Here, we explored the effect of antibody-mediated TREM2 activation on microglia in a well-established toxin-induced model of demyelination in the CNS resulting from exposure to the copper chelator cuprizone (CPZ) in the diet [31].”
From TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“These events lead to OPC recruitment, differentiation into mature OLs, and then remyelination which is almost complete within few weeks from toxin withdrawal [31].”
From TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) · cites this paper as [31]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It may suggest that NODDI could be sensitive biomarkers to probe the different stages of white matter pathology between acute demyelination and chronic demyelination (Matsushima and Morell 2001).”
From Neurite orientation dispersion and density imaging of mouse brain microstructure (2019) · cites this paper as Matsushima and Morell 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Historically these cells are not linked to demyelination following cuprizone treatment because the loss of the V(D)J recombination activation gene-1 (RAG-1), which is critical for B- and T- lymphocyte generation [269], does not alter demyelination and T-cell accumulation in the corpus callosum [46, 270].”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Demyelination peaks between 4.5 and 5 weeks of cuprizone exposure in the CC and between 5 and 6 weeks in the cortex and hippocampus (Hiremath et al., 1998; Matsushima and Morell, 2001; Skripuletz et al., 2008; Gudi et al., 2009; Koutsoudaki et al., 2009).”
From Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned (2014) · cites this paper as Matsushima and Morell, 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Strong astrogliosis comprising hypertrophy and hyperplasia of astrocytes occurs as a response to cuprizone treatment in different white and gray matter structures for instance the CC (Matsushima and Morell, 2001; Gudi et al., 2009), hippocampus, (Koutsoudaki et al., 2009; Norkute et al., 2009), cerebellum, cortex (Skripuletz et al., 2008), and basal ganglia (Pott et al., 2009).”
From Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned (2014) · cites this paper as Matsushima and Morell, 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Astrogliosis is an additional pathological hallmark of CUP treatment (Matsushima & Morell, 2001).”
From Activated microglia drive demyelination via CSF1R signaling (2021) · cites this paper as Matsushima & Morell, 2001
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Streit, W. J., Walter, S. A., & Pennell, N. A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00069-0 · Cited by 1,096
Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice
Hiremath, M. M., Saito, Y., Knapp, G. W., Ting, J. P.-Y., Suzuki, K., & Matsushima, G. K. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00168-4 · Cited by 412
Self-citation(1978) · PubMed · Cited by 297
Nishiyama, A., Lin, X., Giese, N. A., Heldin, C., & Stallcup, W. B. (1996) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19960201)43:3 · Cited by 244
Insulin-Like Growth Factor-1 Inhibits Mature Oligodendrocyte Apoptosis during Primary Demyelination
Mason, J. L., Ye, P., Suzuki, K., D'Ercole, A. J., & Matsushima, G. K. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05703.2000 · Cited by 237
Self-citationKomoly, S., Hudson, L. D., Webster, H. D., & Bondy, C. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1894 · Cited by 223
Blakemore, W. F. (1972) · Journal of Neurocytology · doi:10.1007/bf01102943 · Cited by 217
Gene Expression in Brain during Cuprizone-Induced Demyelination and Remyelination
Morell, P., Barrett, C. V., Mason, J. L., Toews, A. D., Hostettler, J. D., Knapp, G. W., & Matsushima, G. K. (1998) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1998.0715 · Cited by 213
Self-citationDemyelination of the superior cerebellar peduncle in the mouse induced by cuprizone
Blakemore, W. F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90118-4 · Cited by 207
Blakemore, W. F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90119-6 · Cited by 177
Research works printed but not linked: 2
- Jurevics HA, 2000, Lipid metabolism during remyelination in brain, J Neurochem, 74, S32
- Ludwin SK, 1980, Chronic demyelination inhibits remyelination in the central nervous system, Lab Invest, 43, 382
Cited by
Sorted by citations
Items 401–500 of 985
Palumbo, S., & Bosetti, F. (2013) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2013.08.008 · Cited by 35
Zinnhardt, B., Belloy, M., Fricke, I. B., Orije, J., Guglielmetti, C., Hermann, S., Wagner, S., Schäfers, M., Van der Linden, A., & Jacobs, A. H. (2019) · Theranostics · doi:10.7150/thno.32461 · Cited by 36
Approaches to Remyelination Therapies in Multiple Sclerosis
Wooliscroft, L., Silbermann, E., Cameron, M. H., & BOURDETTE, D. N. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0574-1 · Cited by 36
Lee, J., Villarreal, O. D., Chen, X., Zandee, S., Young, Y. K., Torok, C., Lamarche-Vane, N., Prat, A., Rivest, S., Gosselin, D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108560 · Cited by 38
Yamamoto, S., Gotoh, M., Kawamura, Y., Yamashina, K., Yagishita, S., Awaji, T., Tanaka, M., Maruyama, K., Murakami‐Murofushi, K., & Yoshikawa, K. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.040 · Cited by 35
Tomàs-Roig, J., Wirths, O., Salinas, G., & Havemann‐Reinecke, U. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12506 · Cited by 35
Barthelmes, J., Tafferner, N., Kurz, J., de Bruin, N. M. W. J., Parnham, M. J., Geißlinger, G., & Schiffmann, S. (2016) · Journal of Visualized Experiments · doi:10.3791/53933 · Cited by 42
Cerina, M., Narayanan, V., Göbel, K., Bittner, S., Ruck, T., Meuth, P., Herrmann, A. M., Stangel, M., Gudi, V., Skripuletz, T., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.08.014 · Cited by 36
Modelling MS: Chronic-Relapsing EAE in the NOD/Lt Mouse Strain
Dang, P. T., Bui, Q., D’Souza, C. S., & Orian, J. M. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_378 · Cited by 35
Han, S. R., Kang, Y. H., Jeon, H., Lee, S., Park, S., Song, D., Min, S. S., Min, S. S., Lee, M., & Lee, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020646 · Cited by 37
Aziz, A. E. A. E., Sayed, R. H., Sallam, N. A., & Sayed, N. S. E. (2021) · Inflammation · doi:10.1007/s10753-021-01447-6 · Cited by 34
In vitro and in vivo induction and activation of nNOS by LPS in oligodendrocytes
Yao, S., Ljunggren‐Rose, A., Chandramohan, N., Whetsell, W. O., & Sriram, S. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.07.023 · Cited by 34
Oligodendrocyte Maturation Alters the Cell Death Mechanisms That Cause Demyelination
Chapman, T. W., Kamen, Y., Piedra, E. T., & Hill, R. A. (2024) · The Journal of Neuroscience · doi:10.1523/jneurosci.1794-23.2024 · Cited by 33
Scott‐Hewitt, N., Folts, C. J., Hogestyn, J. M., Piester, G., Mayer-Pröschel, M., & Noble, M. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx153 · Cited by 32
Qki is an essential regulator of microglial phagocytosis in demyelination
Ren, J., Dai, C., Zhou, X., Barnes, J. A., Chen, X., Wang, Y., Yuan, L., Shingu, T., Heimberger, A. B., Chen, Y., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20190348 · Cited by 36
Liu, Y., Su, Y., Guo, F., Zhang, H., Zhao, Y., Huang, Q., & Xu, H. (2020) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2020.556839 · Cited by 35
CNS-specific expression of C3a and C5a exacerbate demyelination severity in the cuprizone model
Ingersoll, S. A., Martin, C. B., Barnum, S. R., & Martin, B. K. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.08.007 · Cited by 33
Palumbo, S., Toscano, C. D., Parente, L., Weigert, R., & Bosetti, F. (2011) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2011.04.001 · Cited by 33
Role of Dopamine D2 Receptor in Stress-Induced Myelin Loss
Choi, M.-H., Na, J. E., Yoon, Y. R., Lee, H. J., Yoon, S., Rhyu, I. J., & Baik, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-10173-9 · Cited by 32
Low-level laser therapy modulates demyelination in mice
Duarte, K. C. N., Soares, T. T., Magri, A. M. P., Garcia, L. A., Sueur, L. D. P. L., Rennó, A. C. M., & de Castro, G. M. (2018) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2018.09.024 · Cited by 32
Clozapine administration enhanced functional recovery after cuprizone demyelination
Templeton, N., Kivell, B. M., McCaughey‐Chapman, A., Connor, B. J., & Flamme, A. C. L. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216113 · Cited by 30
Mathieu, P., Gubiani, M. F. A., Rodríguez, D., Pinto, L. I. G., Calcagno, M. D. L., & Adamo, A. M. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz130 · Cited by 34
Huang, S., Choi, M. H., Huang, H., Wang, X., Chang, Y. C., & Kim, J. Y. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108394 · Cited by 32
Central Nervous System Pericytes Contribute to Health and Disease
Girolamo, F., Errede, M., Bizzoca, A., Virgintino, D., & Ribatti, D. (2022) · Cells · doi:10.3390/cells11101707 · Cited by 32
Iwasa, K., Yamamoto, S., Takahashi, M., Suzuki, S., Yagishita, S., Awaji, T., Maruyama, K., & Yoshikawa, K. (2014) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2014.08.004 · Cited by 32
Bonetto, G., Charalampopoulos, I., Gravanis, A., & Karagogeos, D. (2017) · Glia · doi:10.1002/glia.23170 · Cited by 33
Skripuletz, T., Miller, E., Grote, L., Gudi, V., Pul, R., Voss, E., Škuljec, J., Moharregh-Khiabani, D., Trebst, C., & Stangel, M. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.05.009 · Cited by 31
The crucial role of Erk2 in demyelinating inflammation in the central nervous system
Okazaki, R., Doi, T., Hayakawa, K., Morioka, K., Imamura, O., Takishima, K., Hamanoue, M., Sawada, Y., Nagao, M., Tanaka, S., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0690-8 · Cited by 31
Maganti, R. J., Hronowski, X. L., Dunstan, R. W., Wipke, B. T., Zhang, X., Jandreski, L., Hamann, S., & Juhász, P. (2018) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155418815860 · Cited by 33
Genovese, G., Palombo, M., Santin, M. D., Valette, J., Ligneul, C., Aigrot, M., Abdoulkader, N., Langui, D., Millecamps, A., Baron‐Van Evercooren, A., et al. (2021) · NMR in Biomedicine · doi:10.1002/nbm.4480 · Cited by 31
Cuprizone-induced Demyelination in Mouse Brain is not due to Depletion of Copper
Morgan, M. L., Teo, W., Hernandez, Y., Brideau, C., Cummins, K., Kuipers, H. F., & Stys, P. K. (2022) · ASN NEURO · doi:10.1177/17590914221126367 · Cited by 32
Tejedor, L. S., Berner, G., Jacobsen, K. T., Gudi, V., Jungwirth, N., Hansmann, F., Gingele, S., Prajeeth, C. K., Baumgärtner, W., Hoffmann, A., et al. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.06.024 · Cited by 31
Chew, L., & DeBoy, C. A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.06.008 · Cited by 32
Zhang, J., Sun, X., Zheng, S., Liu, X., Jin, J., Ren, Y., & Luo, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108646 · Cited by 31
Vitamin K enhances the production of brain sulfatides during remyelination
Popescu, D. C., Huang, H., Singhal, N. K., Shriver, L. P., McDonough, J. A., Clements, R. J., & Freeman, E. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203057 · Cited by 31
Schmidt, H., Raasch, J., Merkler, D., Klinker, F., Krauss, S., Brück, W., & Prinz, M. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2008.12.002 · Cited by 31
Demyelinating diseases and potential repair strategies
Radtke, C., Spies, M., Sasaki, M., Vogt, P. M., & Kocsis, J. D. (2007) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2007.02.002 · Cited by 32
Truong, P. H., Ciccotosto, G. D., Merson, T. D., Spoerri, L., Chuei, M. J., Ayers, M. M., Xing, Y. L., Emery, B., & Cappai, R. (2018) · Glia · doi:10.1002/glia.23561 · Cited by 29
Astroglial and oligodendroglial markers in the cuprizone animal model for de- and remyelination
Castillo-Rodriguez, M. D. L. A., Gingele, S., Schröder, L., Möllenkamp, T. M., Stangel, M., Skripuletz, T., & Gudi, V. (2022) · Histochemistry and Cell Biology · doi:10.1007/s00418-022-02096-y · Cited by 33
Zhang, H., Wang, D., Sun, J., Wang, Y., Wu, S., & Wang, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416182 · Cited by 33
Iron and copper in progressive demyelination – New lessons from Skogholt's disease
Aspli, K. T., Flaten, T. P., Roos, P. M., Holmøy, T., Skogholt, J. H., & Aaseth, J. (2014) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2014.12.002 · Cited by 36
Thymic Atrophy and Apoptosis of CD4+CD8+ Thymocytes in the Cuprizone Model of Multiple Sclerosis
Solti, I., Kvell, K., Talaber, G., Veto, S., Acs, P., Gallyas, F., Illes, Z., Fekete, K., Zalan, P., Szanto, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0129217 · Cited by 30
Corrales, A. V. G., Verberk, S. G. S., Haidar, M., Grajchen, E., Dehairs, J., Vanherle, S., Loix, M., Weytjens, T., Gervois, P., Matsuzaka, T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2301030120 · Cited by 30
Galloway, D. A., Carew, S. J., Blandford, S. N., Benoit, R. Y., Fudge, N. J., Berry, T., Moore, G. R. W., Barron, J., & Moore, C. S. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15650 · Cited by 31
Herder, V., Hansmann, F., Stangel, M., Schaudien, D., Röhn, K., Baumgärtner, W., & Beineke, A. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.01.010 · Cited by 29
Clarner, T., Buschmann, J., Beyer, C., & Kipp, M. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9419-9 · Cited by 29
Melamed, E., Palmer, J. L., & Fonken, C. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1019877 · Cited by 26
Paving the way for adequate myelination: The contribution of galectin‐3, transferrin and iron
Franco, P. G., Pasquini, L. A., Pérez, M. J., Rosato‐Siri, M. V., Silvestroff, L., & Pasquini, J. M. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.08.001 · Cited by 29
Limited TCF7L2 Expression in MS Lesions
Lürbke, A., Hagemeier, K., Cui, Q., Metz, I., Brück, W., Antel, J. P., & Kuhlmann, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072822 · Cited by 28
Biological models in multiple sclerosis
Sanabria‐Castro, A., Flores-Díaz, M., & Alape‐Girón, A. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24528 · Cited by 29
Manousi, A., Göttle, P., Reiche, L., Cui, Q., Healy, L. M., Akkermann, R., Gruchot, J., Schira‐Heinen, J., Antel, J. P., Hartung, H.-P., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103276 · Cited by 28
Animal Models of Multiple Sclerosis
Smith, P. (2021) · Current Protocols · doi:10.1002/cpz1.185 · Cited by 32
Alterations of juxtaparanodal domains in two rodent models of CNS demyelination
Zoupi, L., Markoullis, K., Kleopa, K. A., & Karagogeos, D. (2013) · Glia · doi:10.1002/glia.22511 · Cited by 29
Vakilzadeh, G., Khodagholi, F., Ghadiri, T., Darvishi, M., Ghaemi, A., Noorbakhsh, F., Gorji, A., & Sharifzadeh, M. S. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8857-8 · Cited by 30
RetractedPaez, P. M., Cheli, V. T., Ghiani, C. A., Spreuer, V., Handley, V., & Campagnoni, A. T. (2012) · Glia · doi:10.1002/glia.22336 · Cited by 30
Dock3 protects myelin in the cuprizone model for demyelination
Namekata, K., Kimura, A. K., Harada, C., Yoshida, H., Matsumoto, Y., & Harada, T. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.357 · Cited by 27
Pazhoohan, S., Satarian, L., Asghari, A.-A., Salimi, M., Kiani, S., Mani, A. R., & Javan, M. (2013) · Neurodegenerative Diseases · doi:10.1159/000352021 · Cited by 31
Gat‐Viks, I., Geiger, T., Barbi, M., Raini, G., & Elroy‐Stein, O. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13142 · Cited by 28
A cord blood monocyte–derived cell therapy product accelerates brain remyelination
Saha, A., Buntz, S., Scotland, P., Xu, L., Noeldner, P. K., Patel, S. A., Wollish, A., Gunaratne, A., Gentry, T., Troy, J. D., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86667 · Cited by 28
Self-citationMonti, M. C., Guido, D., Montomoli, C., Sardu, C., Sanna, A., Pretti, S., Lorefice, L., Marrosu, M. G., Valera, P., & Cocco, E. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163313 · Cited by 28
Tan, G. A., Furber, K. L., Thangaraj, M. P., Sobchishin, L., Doucette, J. R., & Nazarali, A. J. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0529-6 · Cited by 31
Yi, Y. (2021) · NeuroImmunoModulation · doi:10.1159/000516064 · Cited by 28
Yamate-Morgan, H., Lauderdale, K., Horeczko, J., Merchant, U., & Tiwari-Woodruff, S. K. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.01.038 · Cited by 27
Zhang, L., Xu, S., Huang, Q., & Xu, H. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24189 · Cited by 28
Naghibzadeh, M., Ranjbar, R., Tabandeh, M. R., & Habibi, A. (2018) · International Journal of Sports Medicine · doi:10.1055/a-0608-4635 · Cited by 28
The TAM receptor TYRO3 is a critical regulator of myelin thickness in the central nervous system
Blades, F., Aprico, A., Akkermann, R., Ellis, S. L., Binder, M. D., & Kilpatrick, T. J. (2018) · Glia · doi:10.1002/glia.23481 · Cited by 26
Guglielmetti, C., Boucneau, T., Cao, P., der Linden, A. V., Larson, P. E. Z., & Chaumeil, M. M. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.116415 · Cited by 27
Arnett, H. A., & VINEY, J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.013 · Cited by 27
Armstrong, R. C. (2007) · Future Neurology · doi:10.2217/14796708.2.6.689 · Cited by 27
Yoshikawa, K., Takei, S., Hasegawa‐Ishii, S., Chiba, Y., Furukawa, A., Kawamura, N., Hosokawa, M., Woodward, D. F., Watanabe, K., & Shimada, A. (2010) · Brain Research · doi:10.1016/j.brainres.2010.10.019 · Cited by 26
Zhou, W., Xia, S., Wang, C., Yang, Q., Verkhratsky, A., & Niu, J. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07893-6 · Cited by 31
Dose-dependent effect of cannabinoid WIN-55,212-2 on myelin repair following a demyelinating insult
Tomàs-Roig, J., Agbemenyah, H. Y., Celarain, N., Quintana, E., Ramió‐Torrentà, L., & Havemann‐Reinecke, U. (2020) · Scientific Reports · doi:10.1038/s41598-019-57290-1 · Cited by 26
Motavaf, M., Sadeghizadeh, M., Babashah, S., Zare, L., & Javan, M. (2020) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.3110 · Cited by 26
Bauch, J., & Faissner, A. (2022) · Cells · doi:10.3390/cells11111773 · Cited by 27
Zhang, L., Yu, W., Schroedter, I., Kong, J., & Vrontakis, M. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033901 · Cited by 26
A novel model of demyelination and remyelination in a GFP-transgenic zebrafish
Fang, Y., Lei, X., Li, X., Chen, Y., Xu, F., Feng, X., Wei, S., & Li, Y. (2014) · Biology Open · doi:10.1242/bio.201410736 · Cited by 26
Glial precursor cell transplantation therapy for neurotrauma and multiple sclerosis
Kulbatski, I., Mothe, A. J., Parr, A. M., Kim, H. S., Kang, C. E., Bozkurt, G., & Tator, C. H. (2008) · Progress in Histochemistry and Cytochemistry · doi:10.1016/j.proghi.2008.04.001 · Cited by 26
Vanherle, S., Guns, J., Loix, M., Mingneau, F., Dierckx, T., Wouters, F., Kuipers, K., Vangansewinkel, T., Wolfs, E., Lins, P. M. P., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12394 · Cited by 28
Krämer, J., Brück, W., Zipp, F., Cerina, M., Groppa, S., & Meuth, S. G. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101663 · Cited by 27
Luo, M., Deng, M., Yu, Z., Zhang, Y., Xu, S., Hu, S., & Xu, H. (2020) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2020.00030 · Cited by 26
Martínez‐Pinilla, E., Rubio-Sardón, N., Villar‐Conde, S., Navarro, G., del Valle, E., Tolivia, J., Franco, R., & Navarro, A. (2021) · Brain Sciences · doi:10.3390/brainsci11020272 · Cited by 27
Wang, Z., Baharani, A., Wei, Z., Truong, D., Bi, X., Wang, F., Li, X., Verge, V. M. K., & Zhang, Y. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13490 · Cited by 26
Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases
Mekhaeil, M., Dev, K. K., & Conroy, M. J. (2022) · Cancers · doi:10.3390/cancers14030687 · Cited by 25
Visual Evoked Potentials to Monitor Myelin Cuprizone-Induced Functional Changes
Marenna, S., Huang, S.-C., Dalla Costa, G., d’Isa, R., Castoldi, V., Rossi, E., Comi, G., & Leocani, L. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.820155 · Cited by 25
Zhang, T., Feng, T., Wu, K., Guo, J. D., Nana, A. L., Yang, G., Seeley, W. W., & Hu, F. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02578-w · Cited by 27
Glenn, J. D., Smith, M. D., Kirby, L. A., Baxi, E. G., & Whartenby, K. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139008 · Cited by 25
Expression Profiles of Metallothionein I/II and Megalin in Cuprizone Model of De- and Remyelination
Jakovac, H., Kezele, T. G., & Radošević-Stašić, B. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.07.009 · Cited by 25
Nystad, A. E., Lereim, R. R., Wergeland, S., Oveland, E., Myhr, K., Bø, L., & Torkildsen, Ø. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.577091 · Cited by 25
Overexpression of myelin-associated glycoprotein after axotomy of the perforant pathway
Mingorance, A., Fontana, X., Soriano, E., & del Río, J. A. (2005) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.03.016 · Cited by 24
Jia, Y., Li, H., Bao, H.-K., Zhang, D., Feng, L., Xiao, Y., Zhu, K.-C., Hou, Y., Luo, S.-L., Zhang, Y., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105777 · Cited by 22
P2x7 receptors control demyelination and inflammation in the cuprizone model
Bernal‐Chico, A., Manterola, A., Cipriani, R., Katona, I., Matute, C., & Mato, S. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100062 · Cited by 24
Yamamoto, S., Sakemoto, C., Iwasa, K., Maruyama, K., Shimizu, K., & Yoshikawa, K. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.08.002 · Cited by 24
Naeem, A. G., El‐Naga, R. N., & Michel, H. E. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01045-4 · Cited by 25
Sex chromosome complement influences functional callosal myelination
Moore, S. M., Patel, R., Hannsun, G., Yang, J., & Tiwari-Woodruff, S. K. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.017 · Cited by 24
Zhang, H., Zhang, Y., Xu, H., Wang, L., Adilijiang, A., Wang, J., Hartle, K. D., Zhang, Z., Zhang, D., Tan, Q., et al. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.02.019 · Cited by 24
Remyelinating strategies in multiple sclerosis
Luessi, F., Kuhlmann, T., & Zipp, F. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.969241 · Cited by 24
Tejedor, L. S., Wostradowski, T., Gingele, S., Skripuletz, T., Gudi, V., & Stangel, M. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0888-y · Cited by 24
Cui, C., Wang, J., Mullin, A. P., Caggiano, A. O., Parry, T. J., Colburn, R. W., & Pavlopoulos, E. (2018) · Brain Research · doi:10.1016/j.brainres.2018.05.013 · Cited by 24
Changes in neurosteroidogenesis during demyelination and remyelination in cuprizone‐treated mice
Leicaj, M. L., Pasquini, L. A., Lima, A. E., Deniselle, M. C. G., Pasquini, J. M., Nicola, A. F. D., & Garay, L. I. (2018) · Journal of Neuroendocrinology · doi:10.1111/jne.12649 · Cited by 26
Accelerating quantitative susceptibility imaging acquisition using compressed sensing
Wang, N., Cofer, G. P., Anderson, R. J., Qi, Y. P., Liu, C., & Johnson, G. A. (2018) · Physics in Medicine and Biology · doi:10.1088/1361-6560/aaf15d · Cited by 24
Metadata
- Authors
- Matsushima, G. K., & Morell, P.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Matsushima, Glenn K.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2001-01
- Volume
- 11
- Issue
- 1
- Pages
- 107-116
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- PMC
- PMC8098267
- OpenAlex
- W2100904149
- Cited by
- 984
- References
- 45
- Citations by year
- 2026: 31 · 2025: 38 · 2024: 42 · 2023: 50 · 2022: 58 · 2021: 48 · 2020: 55 · 2019: 75 · 2018: 59 · 2017: 65 · 2016: 39 · 2015: 58 · 2014: 39 · 2013: 53 · 2012: 40
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain Pathology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ns011615-29, 5r01ns037815-05, 5r29ns035372-05)
- National Institute of Neurological Disorders and Stroke (NS37815, NS-11615, NS-35372)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- cuprizone, demyelination, remyelination, oligodendrocyte apoptosis, microglia, myelin phagocytosis, oligodendrocyte precursor cells, myelin gene expression, C57BL/6 mice, copper chelators
- MeSH terms
- Animals, Central Nervous System, Chelating Agents, Cuprizone, Demyelinating Diseases, Mice, Inbred C57BL, Myelin Sheath, Oligodendroglia, Microglia, Models, Animal, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
